Pilar Martı́nez
A5101681401- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Inflammatory Bowel Disease
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Eosinophilic Esophagitis
- Microscopic Colitis
- Advanced Breast Cancer Therapies
- Histone Deacetylase Inhibitors Research
- Hematological disorders and diagnostics
- Stoma care and complications
- Cytomegalovirus and herpesvirus research
- Diagnosis and treatment of tuberculosis
- Adolescent and Pediatric Healthcare
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Autoimmune and Inflammatory Disorders
- Pregnancy and Medication Impact
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2025
Universidad Autónoma de Madrid
2025
Hospital Universitario de La Princesa
2025
Hospital Universitario 12 De Octubre
2010-2024
Hospital Universitario Miguel Servet
2006-2024
Centro de Investigación Biomédica en Red de Cáncer
2023-2024
Hospital Universitario Fundación Alcorcón
2024
Hospital Clínico Universitario Lozano Blesa
2024
Parque Tecnológico de la Salud
2024
Research Institute Hospital 12 de Octubre
2006-2021
TP53 mutations have been described in chronic lymphocytic leukemia (CLL) and associated with poor prognosis retrospective studies. We aimed to address the frequency prognostic value of abnormalities patients CLL context a prospective randomized trial.We analyzed 529 samples from LRF CLL4 (Leukaemia Research Foundation Chronic Lymphocytic Leukemia 4) trial (chlorambucil v fludarabine or without cyclophosphamide) at time random assignment for gene. mutation status was correlated response...
// Lourdes Martín-Martín 1 , Antonio López Belén Vidriales 2 María Dolores Caballero António Silva Rodrigues 3 Silvia Inês Ferreira 4 Margarida Lima 5 Sérgio Almeida 6 Berta Valverde 7 Pilar Martínez 8 Ana Ferrer 9 Jorge Candeias 10 Francisco Ruíz-Cabello 11 Josefa Marco Buadesa 12 Amparo Sempere 13 Neus Villamor 14 Alberto Orfao 1, * Julia Cancer Research Centre (IBMCC, USAL-CSIC), Institute for Biomedical of Salamanca (IBSAL) and Department Medicine Cytometry Service, University (USAL),...
PURPOSE Nucleophosmin 1 ( NPM1) mutations are associated with a favorable prognosis in acute myeloid leukemia (AML) when an internal tandem duplication (ITD) the fms-related tyrosine kinase 3 gene FLT3) is absent FLT3-ITD neg ) or present low allelic ratio ). The 2017 European LeukemiaNet guidelines assume this true regardless of accompanying cytogenetic abnormalities. We investigated validity assumption. METHODS analyzed associations between karyotype and outcome intensively treated...
Promising results have been shown with the combination of ponatinib and chemotherapy in adults Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The PONALFIL (Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia) trial combined (30 mg/d) standard induction consolidation followed by allogeneic hematopoietic stem cell transplant (alloHSCT) newly diagnosed Ph+ ALL patients aged 18 to 60 years. Ponatinib was only given pre-emptively after...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes assess impact of therapeutic approaches adult AML patients with SARS-CoV-2 first wave (March–May 2020). Overall, 108 were included: 51.9% active 70.4% under schedules for AML. Signs symptoms present 96.3% 82.4% received...
The introduction of tyrosine kinase inhibitors (TKI) has significantly changed the outcome children and adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).1 Several phase 2 trials have shown improved outcomes incorporation ponatinib to first-line therapy, either in combination chemotherapy or blinatumomab,2-4 a matching adjusted indirect comparison versus imatinib as frontline treatment for Ph+ ALL showed significant survival advantage over containing...
Abstract Background Current immunotherapy for inflammatory bowel disease (IBD) treatment is based on anti-TNFα, anti-integrin α4β7, anti-IL12/IL23 and anti-IL23 antibodies that have demonstrated to be safe effective. In vivo models are crucial research with biologics, but the literature doses of above-mentioned drugs in IBD scarce, highly variable covers wide ranges. Thus, we aim find optimal dose biologic a DSS-induced colitis model. Methods C57BL/6 mice were randomized into control group...
Abstract The value of measurable residual disease (MRD) in elderly patients with acute myeloid leukemia (AML) is inconsistent between those treated intensive vs hypomethylating drugs, and unknown after semi-intensive therapy. We investigated the role MRD refining complete remission (CR) treatment duration phase 3 FLUGAZA clinical trial, which randomized 283 AML to induction consolidation fludarabine plus cytarabine (FLUGA) 5-azacitidine. After consolidation, continued if was ≥0.01% or...
Abstract Background CPX‐351 is approved for the treatment of therapy related acute myeloid leukemia (t‐AML) and AML with myelodysplastic changes (MRC‐AML). The benefits this over standard chemotherapy has not been addressed in well matched cohorts real‐life patients. Methods Retrospective analysis patients treated as per routine practice. A propensity score matching (PSM) was used to compare their main outcomes those observed a cohort among 765 historical receiving intensive (IC), all them...
Background Telemonitoring for inflammatory bowel disease (IBD) has not consistently demonstrated superiority over standard care; however, noninferiority may be an acceptable outcome if remote care proves to more efficient. Objective This study aims compare the remission time and quality of life patients with active IBD managed through versus TECCU (Telemonitoring Crohn Disease Ulcerative Colitis) app. Methods A 2-arm, randomized, multicenter trial a design was conducted across 24 hospitals...
Kikuchi's disease (KD), or histiocytic necrotizing lymphadenitis, was initially described in Japan 1972. In the following years, several series of cases involving patients different ages, races, and geographic origins were reported, but pediatric reports have been rare. The etiology KD is unknown, although a viral autoimmune hypothesis has suggested. most frequent clinical manifestation consists local generalized adenopathy, some cases, it associated with more general symptoms, multiorganic...
Immunomediated adverse events [IAEs] are the most frequently reported infliximab [IFX]-related events. Combination therapy may reduce their incidence, although this strategy is not recommended in elderly patients. We aimed to compare rates of IFX-related IAEs and loss response [LOR] younger patients.Adult patients ENEIDA registry who had received a first course IFX were identified grouped into two cohorts regarding age at beginning treatment [over 60 years between 18 50 years]. The LOR...
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) R-bendamustine (R-B) are the most common frontline treatment strategies for advanced-stage follicular lymphoma (FL). After R-CHOP induction therapy, using rituximab maintenance therapy notably improves outcomes; however, whether this can be achieved by same approach after R-B is still being determined. This retrospective analysis compared 476 FL patients from 17 GELTAMO centers who received R-based regimens...
Objective: The aim of this study was to analyze the survival children with Wilms tumor and other malignant renal tumors treated TWPINDA-99 protocol. Materials Methods: Between January 1999 December 2013, 226 patients were registered on trial, based National Tumor Study-5. Patient characteristics evaluated. Results: Two hundred seven diagnosed tumor, which represented 91.6% tumors. male female ratio 0.7:1. median age at diagnosis 3.3 years. Stage III most frequent (39.2%). Metastatic disease...
We sought to predict treatment responses and outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status, comparing azacytidine (AZA) fludarabine plus low-dose cytarabine (FLUGA). Mutational profiling using a custom 43-gene next-generation sequencing panel revealed differences profiles between younger patients, several prognostic markers that were useful young ineffective patients. examined...
Acute myeloid leukemia (AML) in the elderly remains a clinical challenge, with five-year overall survival rate below 10%. The current ELN 2017 genetic risk classification considers cytogenetic and mutational characteristics to stratify fit AML patients into different prognostic groups. However, this is not validated for treated non-intensive approach, its performance may be suboptimal context. Indeed, transcriptomic landscape of has been less explored it might help group patients. In study,...